JPH05246822A - Antibacterial agent - Google Patents
Antibacterial agentInfo
- Publication number
- JPH05246822A JPH05246822A JP8468692A JP8468692A JPH05246822A JP H05246822 A JPH05246822 A JP H05246822A JP 8468692 A JP8468692 A JP 8468692A JP 8468692 A JP8468692 A JP 8468692A JP H05246822 A JPH05246822 A JP H05246822A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- antibacterial agent
- affected part
- propionibacterium acnes
- usnic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Furan Compounds (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、プロピオニバクテリウ
ム・アクネスによる皮膚細菌感染症の防止、治療のため
の化粧品、感染症治療のための医薬品等の分野で利用可
能な抗菌剤及びその製造法に関するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an antibacterial agent which can be used in the fields of cosmetics for preventing and treating skin bacterial infections caused by Propionibacterium acnes, pharmaceuticals for treating infectious diseases, and the production thereof. It is about law.
【０００２】[0002]
【従来の技術】皮膚疾患の一つであるニキビの原因は種
々想定されているが、ホルモン活性の増加により皮脂の
分泌がさかんとなり、その皮脂が毛嚢皮脂線に充満、閉
塞して嫌気雰囲気を作り上げた結果、皮膚毛嚢内に常在
する嫌気性のグラム陽性細菌の一種であるプロピオニバ
クテリウム・アクネスが異常繁殖して引き起こすもので
あると考えられている。Background Art Although various causes of acne, which is one of the skin diseases, are supposed, the secretion of sebum is increased due to the increase of hormonal activity, and the sebum is filled and sequestered in the hair follicle sebaceous line to cause an anaerobic atmosphere. As a result, it is considered that Propionibacterium acnes, which is a kind of anaerobic Gram-positive bacterium that is resident in the hair follicles, is caused by abnormal breeding.
【０００３】一方、ウスニン酸やリケステリン酸は地衣
類固有の代謝産物いわゆる地衣成分として知られている
化合物群に含まれる。地衣類はある種の菌類と藻類から
成り立っている共生体であって、植物学的にも、特異な
地位を占める一群の植物である。地衣成分は具体的には
朝比奈らにより分類されている(朝比奈・柴田著「地衣成
分の化学」河出書房(１９４８年))。On the other hand, usnic acid and liquesteric acid are included in a group of compounds known as lichen-specific metabolites, so-called lichen components. Lichens are symbionts consisting of certain fungi and algae, and are a group of plants that occupy a unique position botanically. Lichen components are specifically classified by Asahina et al. (Asahina and Shibata, "Chemistry of Lichen Components", Kawade Shobo (1948)).
【０００４】地衣成分の生理学的意義については、地衣
類の生育が緩慢であることから、微生物の攻撃や小動物
の喰害に対する防御であるとか、また他の菌類とは異な
り日向に生育することから紫外線に対する防御であると
か考えられている。そのため古来から地衣成分はこれら
機能から生じた用途に使用されてきた。しかし、これら
地衣成分の薬理作用についてはほとんど検討されていな
い。Regarding the physiological significance of the lichen component, since the growth of lichen is slow, it is a defense against microbial attack and feeding of small animals, and unlike other fungi, it grows in the sun. It is considered to be protection against ultraviolet rays. Therefore, since ancient times, lichen components have been used for applications resulting from these functions. However, the pharmacological actions of these lichen components have been scarcely studied.
【０００５】[0005]
【発明が解決しようとする課題】サルファ剤や抗生物質
がプロピオニバクテリウム・アクネスによるニキビの治
療剤として利用されているが、当該菌の抵抗性獲得によ
る殺菌効果あるいは増殖抑制効果の低下が顕著になって
きている。一方、病原菌による感染症に対する治療薬の
多くは投薬上安全性の観点から副作用等の点で問題があ
り、常に新たな治療薬を探索していく必要がある。[Problems to be Solved by the Invention] Sulfa drugs and antibiotics are used as therapeutic agents for acne caused by Propionibacterium acnes, but the bactericidal effect or growth inhibitory effect due to the acquired resistance of the bacteria is markedly reduced. It has become to. On the other hand, many therapeutic agents for infectious diseases caused by pathogenic bacteria have problems in terms of side effects and the like from the viewpoint of drug safety, and it is necessary to constantly search for new therapeutic agents.
【０００６】本発明の目的はニキビ原因菌の一つである
プロピオニバクテリウム・アクネスに対する抗菌剤を提
供することにある。An object of the present invention is to provide an antibacterial agent against Propionibacterium acnes which is one of acne-causing bacteria.
【０００７】[0007]
【課題を解決するための手段】本発明が提供することに
成功したプロピオニバクテリウム・アクネスに対する抗
菌剤は、ウスニン酸類またはリケステリン酸類を有効成
分として含有することを特徴とするものである。The antibacterial agent against Propionibacterium acnes successfully provided by the present invention is characterized by containing usnic acid or liquesteric acid as an active ingredient.
【０００８】本発明に係わる有効成分であるウスニン酸
類はジベンゾフラン系の化合物群を広く意味し、ウスニ
ン酸(１)、イソウスニン酸(２)、ジジム酸(３)、プラコ
ジオール酸、パンナ酸、シゾペルツ酸、ストレプシリ
ン、ポリフィリン酸等が挙げられる。Usnic acid, which is an active ingredient according to the present invention, broadly means a group of dibenzofuran compounds, and is usnic acid (1), isousnic acid (2), didimic acid (3), prakodiolic acid, pannaic acid, cizopertuic acid. , Strepcillin, porphyrinic acid and the like.
【０００９】これらの製法は公知であるが、例えばJ.A.
Elix & Ａ'.A.Whiton Progr. Chem.Organ.Nat.Prod.45,
103-234(1984年)に記載された方法により製造される。Although these manufacturing methods are known, for example, JA
Elix &A'.A.Whiton Progr. Chem.Organ.Nat.Prod.45,
It is manufactured by the method described in 103-234 (1984).
【００１０】また、リケステリン酸類は脂肪酸ラクトン
系の化合物群を広く意味し、リケステリン酸(４)、プロ
トリケステリン酸(５)、ネフロステリン酸(６)、アカレ
ン酸、アカラン酸、ネフロステラン酸、ネフロモプシン
酸、ロクセラ酸等が挙げられる。Further, liquesteric acids broadly mean a group of fatty acid lactone compounds, and include liquesteric acid (4), protricesteric acid (5), nefosteric acid (6), acalenic acid, acaranic acid, nephrosteranic acid, neflomopsinic acid. , Roxeric acid and the like.
【００１１】これらの製法も公知であるが、例えば朝比
奈・柴田著「地衣成分の化学」p17〜19に記載されて方法
により製造される。Although these production methods are also known, for example, they are produced by the method described in "Chemistry of Lichen Components", pages 17 to 19 by Asahina and Shibata.
【００１２】本発明の抗菌剤の投与方法は患部に直接塗
布する外用的用法が一般的であるが、経口投与してもよ
い。外用剤は溶液、乳液、軟膏として用いられる。ま
た、本発明の抗菌剤を他の組成物(例えば、化粧料)に加
えて使用してもよい。The antibacterial agent of the present invention is generally administered externally by direct application to the affected area, but it may be orally administered. The external preparation is used as a solution, emulsion or ointment. In addition, the antibacterial agent of the present invention may be used in addition to other compositions (for example, cosmetics).
【００１３】本発明の抗菌剤の投与量は患部面積、その
他の要因で大きく変化するが、例えば有効成分を０.０
０１〜１０％含むものを１日数回患部にうすく塗布す
る。The dose of the antibacterial agent of the present invention varies greatly depending on the affected area and other factors.
Those containing 01 to 10% are thinly applied to the affected area several times a day.
【００１４】[0014]
【発明の効果】ウスニン酸類、リケステリン酸類は、極
めて安定であり、プロピオニバクテリウム・アクネスに
起因するニキビの防止、治療のための化粧品に利用用可
能な極めて有用なものである。INDUSTRIAL APPLICABILITY Usnic acids and liquesteric acids are extremely stable and extremely useful for cosmetics for the prevention and treatment of acne caused by Propionibacterium acnes.
【００１５】[0015]
【実施例】以下に実施例を示すが、本発明はこれら実施
例に限定されない。EXAMPLES Examples will be shown below, but the present invention is not limited to these examples.
【００１６】(実施例)表１に示す地衣成分をアセトンに
溶解し、１０-6g／ml溶液を作製した。５０μlのアセト
ン溶液を染み込ませた濾紙ディスク(径８mm)を、予めプ
ロピオバクテリウム・アクネスを播種した寒天平板(径
９０mm)上に同一サンプルにつき２枚づつ置き、３７℃
で４８時間嫌気培養し、その阻止円の大きさで抗菌活性
を測定した。(Example) The lichen components shown in Table 1 were dissolved in acetone to prepare a 10 -6 g / ml solution. Place two filter paper discs (diameter 8 mm) soaked with 50 μl of acetone solution on the agar plate (diameter 90 mm) seeded with Propiobacterium acnes in duplicate for each sample and 37 ° C.
Anaerobic culture was carried out for 48 hours, and the antibacterial activity was measured by the size of the inhibition circle.
【００１７】 [0017]
フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 ＦＩ 技術表示箇所 Ｃ０７Ｄ 307/91 (72)発明者 山本 好和 大阪府寝屋川市池田中町19番17号 日本ペ イント株式会社内 (72)発明者 真山 滋志 兵庫県西宮市枝川町17−２−243Front page continuation (51) Int.Cl. 5 Identification number Reference number within the agency FI Technical indication location C07D 307/91 (72) Inventor Yoshikazu Yamamoto 19-17 Ikedanaka-cho, Neyagawa-shi, Osaka Japan Paint Co., Ltd. (72) Inventor Shigeru Mayama 17-2-243 Edagawa-cho, Nishinomiya-shi, Hyogo
Claims (1)
含有することを特徴とするプロピオニバクテリウム・ア
クネス(Ｐropionibacterium acnes)に対する抗菌剤。1. An antibacterial agent against Propionibacterium acnes, which contains usnic acid or liquesteric acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8468692A JPH05246822A (en) | 1992-03-07 | 1992-03-07 | Antibacterial agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8468692A JPH05246822A (en) | 1992-03-07 | 1992-03-07 | Antibacterial agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH05246822A true JPH05246822A (en) | 1993-09-24 |
Family
ID=13837569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8468692A Pending JPH05246822A (en) | 1992-03-07 | 1992-03-07 | Antibacterial agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH05246822A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005533107A (en) * | 2002-07-01 | 2005-11-04 | ファスゲン，エルエルシー． | NOVEL COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND METHOD OF USING THE SAME |
| GB2486804A (en) * | 2010-12-22 | 2012-06-27 | Evocutis Plc | Antibacterial containing usnic acid/usnate and bismuth or copper salts |
| CN102949298A (en) * | 2011-12-20 | 2013-03-06 | 上海莱博生物科技有限公司 | Application of usnic acid and/or salts thereof |
| JP2015514740A (en) * | 2012-04-18 | 2015-05-21 | サントレ ナスィヨナル ドゥ ラ ルシェルシュ スィヤンティフィック−セエヌエールエス | Liquesteric acid and its derivatives as pigmentation inhibitors |
-
1992
- 1992-03-07 JP JP8468692A patent/JPH05246822A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005533107A (en) * | 2002-07-01 | 2005-11-04 | ファスゲン，エルエルシー． | NOVEL COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND METHOD OF USING THE SAME |
| GB2486804A (en) * | 2010-12-22 | 2012-06-27 | Evocutis Plc | Antibacterial containing usnic acid/usnate and bismuth or copper salts |
| CN102949298A (en) * | 2011-12-20 | 2013-03-06 | 上海莱博生物科技有限公司 | Application of usnic acid and/or salts thereof |
| JP2015514740A (en) * | 2012-04-18 | 2015-05-21 | サントレ ナスィヨナル ドゥ ラ ルシェルシュ スィヤンティフィック−セエヌエールエス | Liquesteric acid and its derivatives as pigmentation inhibitors |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69833131T2 (en) | METAL / THIOL-CONTAINING BIOCIDES | |
| CA2850908C (en) | Aqueous antimicrobial composition containing coniferous resin acids | |
| CA2263473C (en) | Silver-based antimicrobial compositions | |
| GEP20002298B (en) | Benzimidazole Derivatives, Method of Their Production, Pharmaceutical Composition Containing the Same and Method for Its Treatment | |
| EP0382066A3 (en) | Use of dihydroliponic acid as an analgetic, antiphlogistic and/or cytoprotective agent | |
| DE60017133T2 (en) | Naphthoquinone derivatives and their use in the treatment and control of tuberculosis | |
| KR950000142A (en) | Use of hydroxy acid-containing L-carnitine esters and acyl L-carnitine esters for the preparation of pharmaceutical compositions for the treatment of skin diseases | |
| US4132781A (en) | Method for treatment of acne | |
| JPH05246822A (en) | Antibacterial agent | |
| RU2636530C2 (en) | Pharmaceutical compositions for treatment of wounds and burns | |
| BE885605A (en) | BENZO (IJ) QUINOLIZINE-CARBOXYLIC-2 ACID DERIVATIVES USEFUL IN PARTICULAR AS ANTIMICROBIAL DRUGS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITIONS AND PHARMACEUTICAL FORMS CONTAINING THEM | |
| JP2019178170A (en) | Use of patchouli extract in preparation of compositions with anti-microorganism effect | |
| WO2000050019A2 (en) | USE OF R-ARYL PROPIONIC ACIDS FOR PRODUCING MEDICAMENTS TO TREAT DISEASES IN HUMANS AND ANIMALS, WHEREBY SAID DISEASES CAN BE THERAPEUTICALLY INFLUENCED BY INHIBITING THE ACTIVATION OF NF-λB | |
| DE3443985A1 (en) | Pharmaceutical preparations against mycotic and bacterial infections, which contain active ingredients which release zinc in ionised form | |
| DE60035133D1 (en) | PHARMACEUTICAL COMPOSITIONS WITH WOUND HEALING AND ANTI-COMPLEMENTARY EFFECT THAT CONTAIN A DEXTRANDERIVATE | |
| DE69914957T2 (en) | NON-SOLID TOPICALLY APPLICABLE PRODUCT CONTAINING GLYZEROL AND ALCHEMILLA VULGARIS EXTRACT | |
| EP0403575B1 (en) | Acyl carnitine for the treatment and prevention of virus infections | |
| JPH05246876A (en) | Antibacterial agent | |
| DE4024155A1 (en) | Internal use of allicin-urotropin product - to treat bacterial, viral and fungal infections including meningitis, rabies, AIDs, tuberculosis, leprosy, plague and cancer | |
| CN115487226B (en) | External natural bactericide pharmaceutical composition | |
| DE102012000416A1 (en) | Topical composition, useful for treating wounds, preferably open wounds and ulcers, comprises fusafungine and/or one of its derivative and onion extract | |
| CN114096229B (en) | Use of dianhydrohexitols for eliminating the effects of acne, dandruff and malodour on the instrumentation of the appearance | |
| RU1793919C (en) | Composition for bronchopneumonia treatment in animals | |
| CN107998071B (en) | Method for improving stability of phenytoin silver and phenytoin silver external preparation | |
| RU2123854C1 (en) | Agent for treatment of patients with respiratory way infectious sicknesses |